Formulation and Drug Delivery

It’s a Matter of Taste-Masking

December 03, 2021

Increased patient-centricity and alternative dosage forms require careful consideration when selecting the best taste-masking approach.

CordenPharma Adds Highly Potent Capabilities in Germany

December 01, 2021

CordenPharma will build a clinical trial development facility for manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

November 29, 2021

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Vaccine Makers Seek to Address Omicron SARS-CoV-2 Variant

November 29, 2021

The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.

EMA Recommends Pfizer and BioNTech’s COVID-19 Vaccine for Children

November 29, 2021

The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.

EMA Begins Evaluation of Novavax COVID-19 Vaccine Marketing Authorization Application

November 19, 2021

Novavax has announced that EMA has started its review of a conditional marketing authorization application for its COVID-19 vaccine, NVX-CoV2373.

Pfizer Submits COVID-19 Oral Antiviral Candidate to FDA for Emergency Use Authorization

November 17, 2021

Pfizer’s PAXLOVID oral solid-dosage treatment is designed to combat SARS-CoV-2 in high-risk patients at the first sign of infection.

Evolution of Aseptic Processing: INTERPHEX Keynote Part 2

November 16, 2021

Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG, discusses the evolution of aseptic processing with a particular focus on isolators.

Generic-Drug Makers Also Fight Price Controls

November 12, 2021

The Democratic legislative proposal to authorize price negotiations on costly medicines covered by Medicare has drawn opposition from brand pharmaceutical and biotech companies.

EMA Starts Evaluation of Moderna’s COVID-19 Vaccine for Children

November 10, 2021

The agency is evaluating Moderna’s application for use of Spikevax in children aged 6 to 11.